

3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| 5AM Opportunities | 2025 | Indefinite | $25M | 18 |
| 5AM Opportunities Offshore | 2025 | Indefinite | $6.5M | 4 |
| 5AM Ventures VIIFiled to raise in 2021, with no closing reported yet. | 2021 | $450M | $0 | 0 |
| 5AM Opportunities IIFiled to raise in 2021, with no closing reported yet. | 2021 | $300M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Andrew Schwab | Quiet | Biotech & pharma, Digital health, Data & analytics | 19 |
Categories of 5AM Ventures’s own portfolio companies, based on 36 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Excelerate Health Ventures | 19 | Assay Depot, BEKHealth, BIRD ROCK BIO, Camp4 Therapeutics, Cleave Biosciences, Escient Pharmaceuticals, GenePeeks, Huma.AI, Itiliti Health, Nido Biosciences, Pear Therapeutics, Precision Nanosystems, Purigen Biosystems, Radionetics Oncology, RareCyte, Ride Health, S2N Health, Skye Bioscience, TMRW Life Sciences |
| ARCH Venture Partners | 4 | Homology Medicines, Pulmatrix Operating Company, Pulmatrix, Variation Biotechnologies (US) |
| Versant Venture Capital | 4 |
| 2018 |
| $150M |
| $0 |
| 0 |
| 5AM Ventures VIFiled to raise in 2018, with no closing reported yet. | 2018 | $350M | $0 | 0 |
| 5AM Ventures V | May 2016 | $285M | $285M | 80 |
| 0 |
| Anna Yaeger | Quiet | None listed | 0 | 0 |
| Kush Parmar | Quiet | Biotech & pharma | 9 | 0 |
| Scott RocklageNot on the current fund | Quiet | Biotech & pharma, Climate & energy, Manufacturing & industrials | 9 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of 5AM Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Audentes Therapeutics, BIRD ROCK BIO, KINESTRAL TECHNOLOGIES, RENNOVIA |
| Polaris Partners | 3 | Camp4 Therapeutics, Pulmatrix Operating Company, Pulmatrix |
| 270 Healthcare Growth | 2 | ARVINAS HOLDING COMPANY, Audentes Therapeutics |
| Arboretum Ventures | 2 | Pear Therapeutics, RareCyte |
| Frazier Life Sciences | 2 | K2 THERAPEUTICS, Radionetics Oncology |
| Hatteras Venture Partners | 2 | BEKHealth, Huma.AI |
| Nextech Invest | 2 | ARVINAS HOLDING COMPANY, Cleave Biosciences |
| Westlake Biopartners | 2 | Albamunity, Precision Nanosystems |
| Aisling Capital | 1 | K2 THERAPEUTICS |
| Altitude Ventures | 1 | Itiliti Health |
| Asset Management Ventures | 1 | Audentes Therapeutics |
| Bioluminescence Ventures | 1 | Ensoma |
| Cure Ventures | 1 | Entrada Therapeutics |
A shared board seat: a company where filings name a 5AM Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.